产品说明书

Kainic acid

Print
Chemical Structure| 487-79-6 同义名 : -
CAS号 : 487-79-6
货号 : A537335
分子式 : C10H15NO4
纯度 : 98%
分子量 : 213.23
MDL号 : MFCD00077806
存储条件:

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(234.49 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 25 mg/mL(117.24 mM),配合低频超声,并水浴加热至45℃助溶

动物实验配方:
生物活性
描述 Kainic acid is a potent agonist at excitatory amino acid receptor subtypes in the CNS. Kainic acid is a potent neurotoxin, and induces selective neuronal loss in the rat hippocampus. Kainic acid acts on the kainate receptors, and kainic acid neurotoxicity may be in part mediated by oxidative stress[3]. The neurotoxic properties of kainic acid and ibotenic acid following intrahippocampal injection in neonatal rats and found significant pyramidal cell death following injection of 1.0 microgram kainic acid in 6, 7 and 9-day-old pups. At doses 2.5 or five times this amount, significant pyramidal cell loss was obtained in 5-day-old rats as well[4]. The systemic injection of a single low dose (7 mg/kg) of kainic acid to ovariectomized rats produced a marked loss of Nissl-stained and somatostatin-immunoreactive hilar neurons[5]. The kainic acid-induced lesions potentiated the locomotor response to both the dopaminergic agonist, d-amphetamine, and the cholinergic antagonist, scopolamine, attenuated the cataleptic response to the dopaminergic antagonist, haloperidol, and potentiated the cataleptic acid and convulsive responses to the cholinergic agonist, pilocarpine[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02108015 Healthy Volunteers Phase 1 Terminated - United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT03244345 Depression and Epilepsy Not Applicable Recruiting February 20, 2021 France ... 展开 >> Assistance Publique Hôpitaux de Marseille Recruiting Marseille, France, 13354 Contact: Aïleen Mc Gonigal, MD       aileen.mcgonigal@ap-hm.fr    Chu Tours Not yet recruiting Tours, France Contact: Bertrand DE TOFFOL, MD/PhD       bertrand.detoffol@univ-tours.fr 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.69mL

0.94mL

0.47mL

23.45mL

4.69mL

2.34mL

46.90mL

9.38mL

4.69mL

参考文献

[1]Riljak V, Marešova D, et al. Subconvulsive dose of kainic acid transiently increases the locomotor activity of adult Wistar rats. Physiol Res. 2015;64(2):263-7. Epub 2014 Oct 15.

[2]Levesque M, Avoli M. The kainic acid model of temporal lobe epilepsy. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2887-99.

[3]Matsuoka Y, Kitamura Y, Okazaki M, Kakimura J, Tooyama I, Kimura H, Taniguchi T. Kainic acid induction of heme oxygenase in vivo and in vitro. Neuroscience. 1998 Aug;85(4):1223-33

[4]Cook TM, Crutcher KA. Intrahippocampal injection of kainic acid produces significant pyramidal cell loss in neonatal rats. Neuroscience. 1986 May;18(1):79-92

[5]Azcoitia I, Sierra A, Garcia-Segura LM. Estradiol prevents kainic acid-induced neuronal loss in the rat dentate gyrus. Neuroreport. 1998 Sep 14;9(13):3075-9

[6]Sanberg PR, Pisa M, Fibiger HC. Kainic acid injections in the striatum alter the cataleptic and locomotor effects of drugs influencing dopaminergic and cholinergic systems. Eur J Pharmacol. 1981 Sep 24;74(4):347-57